Korean J Radiol.  2014 Feb;15(1):169-172. 10.3348/kjr.2014.15.1.169.

Von Hippel-Lindau Syndrome: Demonstration of Entire Disease Spectrum with 68Ga-DOTANOC PET-CT

• Sharma P
• Dhull VS
• Bal C
• Malhotra A
• Kumar R

• KMID: 1711494
• DOI: http://doi.org/10.3348/kjr.2014.15.1.169

Abstract

Von Hippel-Lindau (VHL) syndrome is a rare neoplastic disorder characterized by central nervous system (CNS) and visceral tumors. We here present 68Ga-labelled [1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid]-1-Nal3-Octreotide positron emission tomography computed tomography findings in a 52 year old female with VHL syndrome, demonstrating both CNS and visceral tumors.

Keyword

Von Hippel-Lindau syndrome; 68Ga-DOTANOC; PET-CT; Hemangioblastoma; RCC; NET

MeSH Terms

Brain Diseases/radionuclide imaging
Female
Humans
Kidney Diseases/radionuclide imaging
Liver Diseases/radionuclide imaging
Middle Aged
Multimodal Imaging/*methods
Organometallic Compounds/diagnostic use
Pancreatic Diseases/radionuclide imaging
Positron-Emission Tomography/*methods
Tomography, X-Ray Computed/*methods
von Hippel-Lindau Disease/*radionuclide imaging
Organometallic Compounds

Figure

• 

  Fig. 1 52-year-old female with Von Hippel-Lindau syndrome. Transaxial contrast enhanced CT (A) of abdomen show large (9.6 × 7.4 × 5.4 cm) mass lesion in region of body and tail of pancreas with intense post contrast enhancement (arrow). Multiple cysts of varying sizes are noted in rest of pancreas (asterix). Also, note tortuous blood vessels in peripancreatic and perisplenic location. Transaxial PET (B) and PET-CT (C) images show intense heterogeneous uptake of 68Ga-labelled [1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid]-1-Nal3-Octreotide (68Ga-DOTANOC) (SUVmax = 18.6) in pancreatic mass (arrow), thus confirming it to be NET. Focal 68Ga-DOTANOC uptake (SUVmax = 13.2) was also seen in segment III of liver (B, C, broken arrow) suggesting liver metastasis from pancreatic NET. This was confirmed at fine needle aspiration cytology. Transaxial contrast enhanced CT (D) of abdomen also shows another mass (7.8 × 5.8 × 5.1 cm) arising from interpolar region of left kidney and showing intense post contrast enhancement (arrow). Multiple feeding vessels are seen to arise from left renal artery and supply mass. These findings were suggestive of RCC. Also noted are bilateral multiple renal cortical cysts (asterix). PET (E) and PET-CT (F) images reveal mild 68Ga-DOTANOC uptake (SUVmax = 3.1) in renal mass (arrow). Transaxial PET (G) and PET-CT (H) images of brain show focal area of 68Ga-DOTANOC uptake (SUVmax = 9.9) in hypodense lesion (2 × 2 cm) in left cerebellum (arrow). Transaxial T2 weighted gadolinium enhanced MRI (I) of brain reveals nodular lesion in lateral half of left cerebellar hemisphere with intense post contrast enhancement (arrow), suggesting hemangioblastoma. Transaxial PET (J) and PET-CT (K) images also revealed focal 68Ga-DOTANOC uptake (SUVmax = 8.3) in lateral part of left globe, corresponding to heterogeneous nodular lesion (arrow). Transaxial T2 weighted gadolinium enhanced MRI (L) showed eccentric nodule in lateral part of left globe with intense post contrast enhancement, suggesting retinal hemangioblastoma (arrow).

Reference

1. Richard S, Graff J, Lindau J, Resche F. Von Hippel-Lindau disease. Lancet. 2004; 363:1231–1234.

2. Fanti S, Ambrosini V, Tomassetti P, Castellucci P, Montini G, Allegri V, et al. Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET. Biomed Pharmacother. 2008; 62:667–671.

3. Maher ER, Iselius L, Yates JR, Littler M, Benjamin C, Harris R, et al. Von Hippel-Lindau disease: a genetic study. J Med Genet. 1991; 28:443–447.

4. Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, et al. von Hippel-Lindau disease. Lancet. 2003; 361:2059–2067.

5. Kumar R, Sharma P, Garg P, Karunanithi S, Naswa N, Sharma R, et al. Role of (68)Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours. Eur Radiol. 2011; 21:2408–2416.

6. Reubi JC, Kvols L. Somatostatin receptors in human renal cell carcinomas. Cancer Res. 1992; 52:6074–6078.

7. Naswa N, Sharma P, Nazar AH, Agarwal KK, Kumar R, Ammini AC, et al. Prospective evaluation of ⁶⁸Ga-DOTA-NOC PET-CT in phaeochromocytoma and paraganglioma: preliminary results from a single centre study. Eur Radiol. 2012; 22:710–719.

8. Maher ER, Neumann HP, Richard S. von Hippel-Lindau disease: a clinical and scientific review. Eur J Hum Genet. 2011; 19:617–623.

9. Reubi JC, Waser B, Laissue JA, Gebbers JO. Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumors: in vitro identification. Cancer Res. 1996; 56:1922–1931.

10. Ambrosini V, Campana D, Allegri V, Opocher G, Fanti S. 68Ga-DOTA-NOC PET/CT detects somatostatin receptors expression in von hippel-lindau cerebellar disease. Clin Nucl Med. 2011; 36:64–65.